{"transactions":[{"id":726427,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T20:16:19.000Z","date":"2026-06-23","kind":"grant","planned":false,"acquired":true,"shares":42553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest on the one year anniversary of June 23rd, 2026 (the \"Grant Date\"), subject to the Reporting Person's continuous service through such date."}],"balance_after":42553,"derivative":{"exercise_price":4.04,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":42553},"source":{"system":"sec-edgar","filing":"0001104659-26-077771","document":"tm2618965-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465926077771/tm2618965-2_4seq1.xml","form_type":"4"}},{"id":740746,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-12T21:27:26.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":2938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":2938,"derivative":{"exercise_price":237,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":2938},"source":{"system":"sec-edgar","filing":"0002001011-26-000103","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000103/edgardoc.xml","form_type":"4"}},{"id":740745,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T21:27:26.000Z","date":"2026-06-11","kind":"sale","planned":false,"acquired":false,"shares":4500,"price":250,"value":1125000.0,"ownership":{"direct":true},"balance_after":102580,"source":{"system":"sec-edgar","filing":"0002001011-26-000103","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000103/edgardoc.xml","form_type":"4"}},{"id":740744,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T21:27:26.000Z","date":"2026-06-10","kind":"sale","planned":false,"acquired":false,"shares":500,"price":250,"value":125000.0,"ownership":{"direct":true},"balance_after":107080,"source":{"system":"sec-edgar","filing":"0002001011-26-000103","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000103/edgardoc.xml","form_type":"4"}},{"id":740743,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T21:27:26.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total number of shares owned has been reduced by 7,825 shares to reflect a reallocation of the reporting person's shares in accordance with his account records."}],"balance_after":107580,"source":{"system":"sec-edgar","filing":"0002001011-26-000103","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000103/edgardoc.xml","form_type":"4"}},{"id":748684,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:46:35.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":25907,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026)."}],"balance_after":69967,"source":{"system":"sec-edgar","filing":"0001376960-26-000002","document":"wk-form4_1780692392.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000137696026000002/wk-form4_1780692392.xml","form_type":"4"}},{"id":770112,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-05-20T12:00:09.000Z","date":"2026-05-18","kind":"purchase","planned":false,"acquired":true,"shares":665,"price":3.75,"value":2493.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.75 to $3.76. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":118118,"source":{"system":"sec-edgar","filing":"0001104659-26-064136","document":"tm2615140-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465926064136/tm2615140-1_4seq1.xml","form_type":"4"}},{"id":772216,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-05-19T12:00:08.000Z","date":"2026-05-15","kind":"purchase","planned":false,"acquired":true,"shares":8971,"price":3.9,"value":34986.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $4.03. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":117453,"source":{"system":"sec-edgar","filing":"0001104659-26-063511","document":"tm2614983-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465926063511/tm2614983-1_4seq1.xml","form_type":"4"}},{"id":978266,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-12-09T00:38:24.000Z","date":"2025-12-08","kind":"exercise","planned":false,"acquired":false,"shares":2034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This Option was previously reported as a Grant of 2,329 shares, which vested in full on May 23, 2016, at an exercise price of $119.3000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer."}],"balance_after":0,"derivative":{"exercise_price":69.51,"expiration_date":"2026-05-23","underlying":"Common Stock","underlying_shares":2034},"source":{"system":"sec-edgar","filing":"0002001011-25-000122","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000122/edgardoc.xml","form_type":"4"}},{"id":978265,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-09T00:38:24.000Z","date":"2025-12-08","kind":"exercise","planned":false,"acquired":true,"shares":2034,"price":69.51,"value":141383.34,"ownership":{"direct":true},"balance_after":71323,"source":{"system":"sec-edgar","filing":"0002001011-25-000122","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000122/edgardoc.xml","form_type":"4"}},{"id":1033487,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-24T21:11:02.000Z","date":"2025-09-23","kind":"sale","planned":false,"acquired":false,"shares":954,"price":171.9237,"value":164015.2098,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $171.7250 to $172.2400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":69289,"source":{"system":"sec-edgar","filing":"0002001011-25-000082","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000082/edgardoc.xml","form_type":"4"}},{"id":1033486,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-24T21:11:02.000Z","date":"2025-09-23","kind":"sale","planned":false,"acquired":false,"shares":4628,"price":170.9643,"value":791222.7804,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $170.6850 to $171.6050. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":70243,"source":{"system":"sec-edgar","filing":"0002001011-25-000082","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000082/edgardoc.xml","form_type":"4"}},{"id":1033485,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-24T21:11:02.000Z","date":"2025-09-23","kind":"sale","planned":false,"acquired":false,"shares":4418,"price":170.4051,"value":752849.7318,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $169.6625 to $170.6600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":74871,"source":{"system":"sec-edgar","filing":"0002001011-25-000082","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000082/edgardoc.xml","form_type":"4"}},{"id":1035635,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2025-09-19T22:57:57.000Z","date":"2025-09-19","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":2.45,"value":2450.0,"ownership":{"direct":true},"balance_after":108482,"source":{"system":"sec-edgar","filing":"0001104659-25-091775","document":"tm2526559-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465925091775/tm2526559-7_4seq1.xml","form_type":"4"}},{"id":1071432,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2025-08-08T23:17:00.000Z","date":"2025-08-07","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") awarded to the Reporting Person on August 7, 2025 (the \"Grant Date\"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date."}],"balance_after":107482,"source":{"system":"sec-edgar","filing":"0001104659-25-075788","document":"tm2523004-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465925075788/tm2523004-9_4seq1.xml","form_type":"4"}},{"id":1085908,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-17T20:43:03.000Z","date":"2025-07-15","kind":"grant","planned":false,"acquired":true,"shares":19506,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on the earlier of the one year anniversary of the date hereof or the date of the annual meeting of stockholders of the Company first held in calendar year 2026 (provided such date is no less than\n50 weeks from the date hereof)."}],"balance_after":44060,"source":{"system":"sec-edgar","filing":"0001005286-25-000091","document":"wk-form4_1752784972.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000091/wk-form4_1752784972.xml","form_type":"4"}},{"id":1100338,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T21:09:09.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":36797,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates."}],"balance_after":36797,"derivative":{"exercise_price":3.22,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":36797},"source":{"system":"sec-edgar","filing":"0001104659-25-063692","document":"tm2519252-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465925063692/tm2519252-4_4seq1.xml","form_type":"4"}},{"id":1100337,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2025-06-27T21:09:09.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":12422,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") awarded to the Reporting Person on June 24, 2025 (the \"Grant Date\"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates."}],"balance_after":92482,"source":{"system":"sec-edgar","filing":"0001104659-25-063692","document":"tm2519252-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465925063692/tm2519252-4_4seq1.xml","form_type":"4"}},{"id":1116963,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-10T23:39:27.000Z","date":"2025-06-06","kind":"grant","planned":false,"acquired":true,"shares":5783,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":5783,"derivative":{"exercise_price":105.99,"expiration_date":"2035-06-06","underlying":"Common Stock","underlying_shares":5783},"source":{"system":"sec-edgar","filing":"0002001011-25-000045","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000045/edgardoc.xml","form_type":"4"}},{"id":1116962,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-10T23:39:27.000Z","date":"2025-06-06","kind":"grant","planned":false,"acquired":true,"shares":1209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":79289,"source":{"system":"sec-edgar","filing":"0002001011-25-000045","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000045/edgardoc.xml","form_type":"4"}},{"id":1176749,"issuer":{"id":9617,"kind":"organization","name":"Anebulo Pharmaceuticals, Inc."},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-08T01:41:36.000Z","date":"2025-04-04","kind":"grant","planned":false,"acquired":true,"shares":4964,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders."}],"balance_after":4964,"derivative":{"exercise_price":1.02,"expiration_date":"2035-04-03","underlying":"Common Stock","underlying_shares":4964},"source":{"system":"sec-edgar","filing":"0001641172-25-003092","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815974/000164117225003092/ownership.xml","form_type":"4"}},{"id":1176748,"issuer":{"id":9617,"kind":"organization","name":"Anebulo Pharmaceuticals, Inc."},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-08T01:41:36.000Z","date":"2025-04-04","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders."}],"balance_after":25000,"derivative":{"exercise_price":1.02,"expiration_date":"2035-04-03","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001641172-25-003092","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815974/000164117225003092/ownership.xml","form_type":"4"}},{"id":1320452,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-30T23:09:05.000Z","date":"2024-12-27","kind":"exercise","planned":false,"acquired":false,"shares":11700,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6900,"derivative":{"exercise_price":4.3,"exercise_date":"2023-01-26","expiration_date":"2028-11-16","underlying":"Common Stock","underlying_shares":11700},"source":{"system":"sec-edgar","filing":"0001104659-24-132582","document":"tm2432271-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465924132582/tm2432271-1_4seq1.xml","form_type":"4"}},{"id":1320451,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2024-12-30T23:09:05.000Z","date":"2024-12-27","kind":"exercise","planned":false,"acquired":true,"shares":11700,"price":4.3,"value":50310.0,"ownership":{"direct":true},"balance_after":80060,"source":{"system":"sec-edgar","filing":"0001104659-24-132582","document":"tm2432271-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465924132582/tm2432271-1_4seq1.xml","form_type":"4"}},{"id":1426851,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-21T23:54:04.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":24554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of July 8, 2025 or the date of the annual meeting of stockholders of the Company first held in calendar year 2025 (provided such date is no less than 50 weeks from July 8, 2024)."}],"balance_after":24554,"source":{"system":"sec-edgar","filing":"0001628280-24-038090","document":"wk-form4_1724284438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024038090/wk-form4_1724284438.xml","form_type":"4"}},{"id":1472166,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-21T21:56:37.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":17068,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":17068,"derivative":{"exercise_price":7.44,"exercise_date":"2025-06-20","expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":17068},"source":{"system":"sec-edgar","filing":"0001104659-24-074012","document":"tm2417742-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465924074012/tm2417742-4_4seq1.xml","form_type":"4"}},{"id":1472165,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2024-06-21T21:56:37.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":5376,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") awarded to the Reporting Person on June 20, 2024. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest on June 20, 2025."}],"balance_after":68360,"source":{"system":"sec-edgar","filing":"0001104659-24-074012","document":"tm2417742-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465924074012/tm2417742-4_4seq1.xml","form_type":"4"}},{"id":1476306,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-06-19T01:25:56.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":5444,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":5444,"derivative":{"exercise_price":80.06,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":5444},"source":{"system":"sec-edgar","filing":"0002001011-24-000055","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000055/edgardoc.xml","form_type":"4"}},{"id":1476305,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-19T01:25:56.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":1252,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":78080,"source":{"system":"sec-edgar","filing":"0002001011-24-000055","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000055/edgardoc.xml","form_type":"4"}},{"id":1477419,"issuer":{"id":9617,"kind":"organization","name":"Anebulo Pharmaceuticals, Inc."},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-17T20:23:45.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":2482,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options vest on the earlier of November 30,2024 or the date of the 2024 annual meeting of shareholders"}],"balance_after":2482,"derivative":{"exercise_price":2.1,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":2482},"source":{"system":"sec-edgar","filing":"0001493152-24-024123","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315224024123/ownership.xml","form_type":"4"}},{"id":1477418,"issuer":{"id":9617,"kind":"organization","name":"Anebulo Pharmaceuticals, Inc."},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-17T20:23:45.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":41667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest 50% on the date of the 2024 annual meeting of shareholders and 50% on the one year anniversary of the date of grant"}],"balance_after":41667,"derivative":{"exercise_price":2.1,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":41667},"source":{"system":"sec-edgar","filing":"0001493152-24-024123","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315224024123/ownership.xml","form_type":"4"}},{"id":1531057,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-05-02T22:07:17.000Z","date":"2024-04-30","kind":"exercise","planned":false,"acquired":false,"shares":2406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This Option was previously reported as a Grant of 2,754 shares, which vested in full on April 24, 2016, at an exercise price of $89.75 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer."}],"balance_after":0,"derivative":{"exercise_price":52.3,"expiration_date":"2025-04-24","underlying":"Common Stock","underlying_shares":2406},"source":{"system":"sec-edgar","filing":"0002001011-24-000050","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000050/edgardoc.xml","form_type":"4"}},{"id":1531056,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-02T22:07:17.000Z","date":"2024-04-30","kind":"exercise","planned":false,"acquired":true,"shares":2406,"price":52.3,"value":125833.8,"ownership":{"direct":true},"balance_after":76828,"source":{"system":"sec-edgar","filing":"0002001011-24-000050","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000050/edgardoc.xml","form_type":"4"}},{"id":1592797,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-03-06T22:28:44.000Z","date":"2024-03-05","kind":"exercise","planned":false,"acquired":false,"shares":2893,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This Option was previously reported as a Grant of 3,312 shares, which vested in full on April 24, 2015, at an exercise price of $67.53 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer."}],"balance_after":0,"derivative":{"exercise_price":39.35,"expiration_date":"2024-06-04","underlying":"Common Stock","underlying_shares":2893},"source":{"system":"sec-edgar","filing":"0002001011-24-000032","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000032/edgardoc.xml","form_type":"4"}},{"id":1592796,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-06T22:28:44.000Z","date":"2024-03-05","kind":"exercise","planned":false,"acquired":true,"shares":2893,"price":39.35,"value":113839.55,"ownership":{"direct":true},"balance_after":74422,"source":{"system":"sec-edgar","filing":"0002001011-24-000032","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000032/edgardoc.xml","form_type":"4"}},{"id":1824236,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-24T22:03:02.000Z","date":"2023-07-20","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":7.42,"exercise_date":"2024-07-20","expiration_date":"2033-07-20","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-23-083523","document":"tm2321855-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465923083523/tm2321855-3_4seq1.xml","form_type":"4"}},{"id":1857832,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-06-13T22:54:10.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":5461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":5461,"derivative":{"exercise_price":73.76,"expiration_date":"2033-06-09","underlying":"Common Stock","underlying_shares":5461},"source":{"system":"sec-edgar","filing":"0000886163-23-000040","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000040/edgardoc.xml","form_type":"4"}},{"id":1857831,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-13T22:54:10.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":1142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":71529,"source":{"system":"sec-edgar","filing":"0000886163-23-000040","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000040/edgardoc.xml","form_type":"4"}},{"id":1884801,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (Right to Buy)","published_at":"2023-05-19T21:42:01.000Z","date":"2023-01-26","kind":"grant","planned":false,"acquired":true,"shares":23250,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 30, 2023, the Reporting Person filed a Form 4 which inadvertently misstated the expiration date of one class of nonstatutory stock options (\"NSOs\"). In accordance with Instruction 9(b) to Form 4, this amendment is filed solely to correct the incorrect expiration date in Table II, Column 6 to August 17, 2032; as provided in that instruction, the remainder of the information in the original filing is not restated in this amendment, and no other amendment is made to the original filing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in the Business Combination in exchange for a nonstatutory stock option to acquire 50,000 shares of Legacy Orchestra Common Stock for $4.65 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The NSOs vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares will vest in equal installments on a quarterly basis on the day of the month of each quarter that is the same day of the month as the grant date, starting with the corresponding date in the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022."}],"balance_after":23250,"derivative":{"exercise_price":10,"expiration_date":"2032-08-17","underlying":"Common Stock","underlying_shares":23250},"source":{"system":"sec-edgar","filing":"0001213900-23-041619","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023041619/ownership.xml","form_type":"4/A","original_submission_date":"2023-01-30"}},{"id":1902976,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Right to Receive Earnout Shares","published_at":"2023-05-06T00:16:20.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":11246,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and 11,246 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and 11,246 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and 11,246 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and 11,246 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and 11,246 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."}],"balance_after":11246,"derivative":{"underlying":"Common Stock","underlying_shares":11246},"source":{"system":"sec-edgar","filing":"0001213900-23-037023","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023037023/ownership.xml","form_type":"4"}},{"id":1902975,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2023-05-06T00:16:20.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":11246,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and 11,246 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and 11,246 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."}],"balance_after":62984,"source":{"system":"sec-edgar","filing":"0001213900-23-037023","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023037023/ownership.xml","form_type":"4"}},{"id":1902964,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Right to Receive Earnout Shares","published_at":"2023-05-05T23:50:00.000Z","date":"2023-01-26","kind":"grant","planned":false,"acquired":true,"shares":22492,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 30, 2023, the Reporting Person filed a Form 4 which inadvertently omitted the right to receive Earnout Shares (defined below). In accordance with Instruction 9(a) to Form 4, this amendment is filed solely to add the lines of information to Table II included here; as provided in that instruction, the remainder of the information in the original filing is not restated in this amendment, and no other amendment is made to the original filing."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."}],"balance_after":22492,"derivative":{"underlying":"Common Stock","underlying_shares":22492},"source":{"system":"sec-edgar","filing":"0001213900-23-037006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023037006/ownership.xml","form_type":"4/A","original_submission_date":"2023-01-30"}},{"id":2042307,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (Right to Buy)","published_at":"2023-01-31T02:31:16.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":23250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in the Business Combination in exchange for a nonstatutory stock option to acquire 50,000 shares of Legacy Orchestra Common Stock for $4.65 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The nonstatutory stock options vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares will vest in equal installments on a quarterly basis on the day of the month of each quarter that is the same day of the month as the grant date, starting with the corresponding date in the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022."}],"balance_after":23250,"derivative":{"exercise_price":10,"expiration_date":"2032-08-25","underlying":"Common Stock","underlying_shares":23250},"source":{"system":"sec-edgar","filing":"0001213900-23-006188","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023006188/ownership.xml","form_type":"4"}},{"id":2042306,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (Right to Buy)","published_at":"2023-01-31T02:31:16.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":6975,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in the Business Combination in exchange for a nonstatutory stock option to acquire 15,000 shares of Legacy Orchestra Common Stock for $2.00 per share."}],"balance_after":6975,"derivative":{"exercise_price":4.3,"exercise_date":"2023-01-26","expiration_date":"2029-08-06","underlying":"Common Stock","underlying_shares":6975},"source":{"system":"sec-edgar","filing":"0001213900-23-006188","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023006188/ownership.xml","form_type":"4"}},{"id":2042305,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (Right to Buy)","published_at":"2023-01-31T02:31:16.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":18600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in the Business Combination in exchange for a nonstatutory stock option to acquire 40,000 shares of Legacy Orchestra Common Stock for $2.00 per share."}],"balance_after":18600,"derivative":{"exercise_price":4.3,"exercise_date":"2023-01-26","expiration_date":"2028-11-16","underlying":"Common Stock","underlying_shares":18600},"source":{"system":"sec-edgar","filing":"0001213900-23-006188","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023006188/ownership.xml","form_type":"4"}},{"id":2042304,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2023-01-31T02:31:16.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":51738,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were issued on the closing date of the merger (the \"Business Combination\") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 and Amendment No. 2 thereto dated as of November 21, 2022 (as amended, the \"Merger Agreement\"), by and among Orchestra BioMed Holdings, Inc. (f/k/a Health Sciences Acquisitions Corporation 2) (\"HSAC2\"), HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation (\"Legacy Orchestra\"), in exchange for Legacy Orchestra securities."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in the Business Combination in exchange for 111,263 shares of common stock of Legacy Orchestra (\"Legacy Orchestra Common Stock\")."}],"balance_after":51738,"source":{"system":"sec-edgar","filing":"0001213900-23-006188","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023006188/ownership.xml","form_type":"4"}},{"id":2076331,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-12-27T23:26:56.000Z","date":"2022-12-22","kind":"grant","acquired":true,"shares":4484,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to reporting person of stock options that will vest and become exercisable on December 22, 2023."}],"balance_after":4484,"derivative":{"exercise_price":67.03,"expiration_date":"2032-12-22","underlying":"Common Stock","underlying_shares":4484},"source":{"system":"sec-edgar","filing":"0000899243-22-039401","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000089924322039401/doc4.xml","form_type":"4"}},{"id":2147555,"issuer":{"id":9617,"kind":"organization","name":"Anebulo Pharmaceuticals, Inc."},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-10-03T23:53:40.000Z","date":"2022-04-21","kind":"grant","acquired":true,"shares":30425,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option vests on March 1, 2023. Thereafter,  1/48 of the option vests on a monthly basis over 36 months until the option becomes fully vested."}],"balance_after":30425,"derivative":{"exercise_price":6,"expiration_date":"2027-02-28","underlying":"Common Stock","underlying_shares":30425},"source":{"system":"sec-edgar","filing":"0001209191-22-051982","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815974/000120919122051982/doc4.xml","form_type":"4"}},{"id":2234873,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-06-13T22:47:51.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":4340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":4340,"derivative":{"exercise_price":79.29,"expiration_date":"2032-06-10","underlying":"Common Stock","underlying_shares":4340},"source":{"system":"sec-edgar","filing":"0000886163-22-000085","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616322000085/edgardoc.xml","form_type":"4"}},{"id":2234872,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-13T22:47:51.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":1004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":69668,"source":{"system":"sec-edgar","filing":"0000886163-22-000085","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616322000085/edgardoc.xml","form_type":"4"}},{"id":2680014,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-06-08T01:39:03.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":3269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":3269,"derivative":{"exercise_price":115.39,"expiration_date":"2031-06-04","underlying":"Common Stock","underlying_shares":3269},"source":{"system":"sec-edgar","filing":"0000886163-21-000094","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616321000094/edgardoc.xml","form_type":"4"}},{"id":2680013,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-08T01:39:03.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":68664,"source":{"system":"sec-edgar","filing":"0000886163-21-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616321000094/edgardoc.xml","form_type":"4"}},{"id":3112447,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2020-06-12T22:35:41.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":2468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2020.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":2468,"derivative":{"exercise_price":117.58,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":2468},"source":{"system":"sec-edgar","filing":"0000886163-20-000080","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616320000080/edgardoc.xml","form_type":"4"}},{"id":3112446,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-12T22:35:41.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":831,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2020. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":68034,"source":{"system":"sec-edgar","filing":"0000886163-20-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616320000080/edgardoc.xml","form_type":"4"}},{"id":3423947,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-04T23:30:35.000Z","date":"2019-09-03","kind":"purchase","acquired":true,"shares":750,"price":87.01,"value":65257.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $86.01 to $88.01, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":67203,"source":{"system":"sec-edgar","filing":"0000886163-19-000163","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616319000163/edgardoc.xml","form_type":"4"}},{"id":3446061,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-06T21:18:05.000Z","date":"2019-08-05","kind":"purchase","acquired":true,"shares":746,"price":90.008,"value":67145.968,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $89.01 to $91.01, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":66453,"source":{"system":"sec-edgar","filing":"0000886163-19-000145","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616319000145/edgardoc.xml","form_type":"4"}},{"id":3452624,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-31T22:50:43.000Z","date":"2019-07-31","kind":"purchase","acquired":true,"shares":754,"price":92.9994,"value":70121.5476,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $91.01 to $94.01, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":65707,"source":{"system":"sec-edgar","filing":"0000886163-19-000132","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616319000132/edgardoc.xml","form_type":"4"}},{"id":3452623,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-31T22:50:43.000Z","date":"2019-07-30","kind":"purchase","acquired":true,"shares":3000,"price":100.2209,"value":300662.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $95.02 to $105.02, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":64953,"source":{"system":"sec-edgar","filing":"0000886163-19-000132","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616319000132/edgardoc.xml","form_type":"4"}},{"id":3452622,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-31T22:50:43.000Z","date":"2019-07-29","kind":"purchase","acquired":true,"shares":250,"price":106.01,"value":26502.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1."}],"balance_after":61953,"source":{"system":"sec-edgar","filing":"0000886163-19-000132","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616319000132/edgardoc.xml","form_type":"4"}},{"id":3459125,"issuer":{"id":95770,"kind":"organization","name":"MERRIMACK PHARMACEUTICALS INC","symbol":"MACK"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common Stock","published_at":"2019-07-18T23:38:02.000Z","date":"2019-07-16","kind":"purchase","acquired":true,"shares":302,"price":5.44,"value":1642.88,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Person disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":3802,"source":{"system":"sec-edgar","filing":"0000921895-19-002020","document":"form412042002_07182019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376960/000092189519002020/form412042002_07182019.xml","form_type":"4"}},{"id":3461861,"issuer":{"id":95770,"kind":"organization","name":"MERRIMACK PHARMACEUTICALS INC","symbol":"MACK"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common Stock","published_at":"2019-07-15T20:32:08.000Z","date":"2019-07-12","kind":"purchase","acquired":true,"shares":1000,"price":5.62,"value":5620.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Person disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":3500,"source":{"system":"sec-edgar","filing":"0000921895-19-002005","document":"form412042002_07152019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1376960/000092189519002005/form412042002_07152019.xml","form_type":"4"}},{"id":3461860,"issuer":{"id":95770,"kind":"organization","name":"MERRIMACK PHARMACEUTICALS INC","symbol":"MACK"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common Stock","published_at":"2019-07-15T20:32:08.000Z","date":"2019-07-12","kind":"purchase","acquired":true,"shares":2400,"price":5.71,"value":13704.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Person disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0000921895-19-002005","document":"form412042002_07152019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1376960/000092189519002005/form412042002_07152019.xml","form_type":"4"}},{"id":3461859,"issuer":{"id":95770,"kind":"organization","name":"MERRIMACK PHARMACEUTICALS INC","symbol":"MACK"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common Stock","published_at":"2019-07-15T20:32:08.000Z","date":"2019-07-11","kind":"purchase","acquired":true,"shares":100,"price":5.71,"value":571.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Person disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0000921895-19-002005","document":"form412042002_07152019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376960/000092189519002005/form412042002_07152019.xml","form_type":"4"}},{"id":3493305,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-12T22:51:10.000Z","date":"2019-06-11","kind":"purchase","acquired":true,"shares":250,"price":107.01,"value":26752.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1."}],"balance_after":61703,"source":{"system":"sec-edgar","filing":"0000886163-19-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616319000115/edgardoc.xml","form_type":"4"}},{"id":3497903,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-06-07T22:55:03.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":4071,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 06, 2019.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":4071,"derivative":{"exercise_price":113.59,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":4071},"source":{"system":"sec-edgar","filing":"0000886163-19-000108","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616319000108/edgardoc.xml","form_type":"4"}},{"id":3497902,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-07T22:55:03.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":835,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 06, 2019. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":61453,"source":{"system":"sec-edgar","filing":"0000886163-19-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616319000108/edgardoc.xml","form_type":"4"}},{"id":3506749,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-31T22:27:11.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":500,"price":108.51,"value":54255.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $108.01 to $109.01, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":60618,"source":{"system":"sec-edgar","filing":"0000886163-19-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616319000090/edgardoc.xml","form_type":"4"}},{"id":3506748,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-31T22:27:11.000Z","date":"2019-05-30","kind":"purchase","acquired":true,"shares":250,"price":110.01,"value":27502.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1."}],"balance_after":60118,"source":{"system":"sec-edgar","filing":"0000886163-19-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616319000090/edgardoc.xml","form_type":"4"}},{"id":3506747,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-31T22:27:11.000Z","date":"2019-05-29","kind":"purchase","acquired":true,"shares":250,"price":111.01,"value":27752.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1."}],"balance_after":59868,"source":{"system":"sec-edgar","filing":"0000886163-19-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616319000090/edgardoc.xml","form_type":"4"}},{"id":3516024,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-22T21:36:49.000Z","date":"2019-05-20","kind":"purchase","acquired":true,"shares":250,"price":112.01,"value":28002.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1."}],"balance_after":59618,"source":{"system":"sec-edgar","filing":"0000886163-19-000085","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616319000085/edgardoc.xml","form_type":"4"}},{"id":3524679,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-16T19:54:31.000Z","date":"2019-05-14","kind":"purchase","acquired":true,"shares":250,"price":112.51,"value":28127.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1."}],"balance_after":59368,"source":{"system":"sec-edgar","filing":"0000886163-19-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616319000083/edgardoc.xml","form_type":"4"}},{"id":3594283,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-15T17:59:23.000Z","date":"2019-03-13","kind":"purchase","acquired":true,"shares":202,"price":112.51,"value":22727.02,"ownership":{"direct":false,"nature":"Indirect"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates  (the \"Funds\").   Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP.   By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds."}],"balance_after":51594,"source":{"system":"sec-edgar","filing":"0000886163-19-000054","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616319000054/edgardoc.xml","form_type":"4"}},{"id":3840841,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-08-17T23:38:36.000Z","date":"2018-08-17","kind":"sale","acquired":false,"shares":26862,"price":241.8122,"value":6495559.3164,"ownership":{"direct":false,"nature":"Indirect"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates  (the \"Funds\").   Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP.   By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds."}],"balance_after":51392,"source":{"system":"sec-edgar","filing":"0000886163-18-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616318000123/edgardoc.xml","form_type":"4"}},{"id":3840840,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-08-17T23:38:36.000Z","date":"2018-08-16","kind":"sale","acquired":false,"shares":1080,"price":245,"value":264600.0,"ownership":{"direct":false,"nature":"Indirect"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates  (the \"Funds\").   Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP.   By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds."}],"balance_after":78254,"source":{"system":"sec-edgar","filing":"0000886163-18-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616318000123/edgardoc.xml","form_type":"4"}},{"id":3876967,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-07-03T22:47:06.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":2474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This amendment is being filed to correct the exercise price listed in item 2 of Table II in order to reflect the market closing price on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":2474,"derivative":{"exercise_price":195.91,"expiration_date":"2028-06-18","underlying":"Common Stock","underlying_shares":2474},"source":{"system":"sec-edgar","filing":"0000886163-18-000100","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616318000100/edgardoc.xml","form_type":"4/A","original_submission_date":"2018-06-21"}},{"id":3886508,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-06-21T20:42:52.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":2474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":2474,"derivative":{"exercise_price":76.77,"expiration_date":"2028-06-18","underlying":"Common Stock","underlying_shares":2474},"source":{"system":"sec-edgar","filing":"0000899243-18-017604","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000089924318017604/doc4.xml","form_type":"4"}},{"id":3886507,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-21T20:42:52.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":493,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":59118,"source":{"system":"sec-edgar","filing":"0000899243-18-017604","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000089924318017604/doc4.xml","form_type":"4"}},{"id":4004278,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-09T23:28:41.000Z","date":"2018-03-09","kind":"sale","acquired":false,"shares":4000,"price":176.4747,"value":705898.8,"ownership":{"direct":false,"nature":"Indirect"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.99 to $177.49, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates  (the \"Funds\").   Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP.   By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds."}],"balance_after":79334,"source":{"system":"sec-edgar","filing":"0000886163-18-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616318000046/edgardoc.xml","form_type":"4"}},{"id":4004277,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-09T23:28:41.000Z","date":"2018-03-08","kind":"sale","acquired":false,"shares":3500,"price":174.8843,"value":612095.05,"ownership":{"direct":false,"nature":"Indirect"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.49 to $175.24, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates  (the \"Funds\").   Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP.   By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds."}],"balance_after":83334,"source":{"system":"sec-edgar","filing":"0000886163-18-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616318000046/edgardoc.xml","form_type":"4"}},{"id":4031769,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-27T23:40:15.000Z","date":"2018-02-23","kind":"sale","acquired":false,"shares":3417,"price":155,"value":529635.0,"ownership":{"direct":false,"nature":"Indirect"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates  (the \"Funds\").   Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP.   By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds."}],"balance_after":86834,"source":{"system":"sec-edgar","filing":"0000886163-18-000028","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616318000028/edgardoc.xml","form_type":"4"}},{"id":4031768,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-27T23:40:15.000Z","date":"2018-02-26","kind":"gift","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Charitable gift to a third party."}],"balance_after":58625,"source":{"system":"sec-edgar","filing":"0000886163-18-000028","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616318000028/edgardoc.xml","form_type":"4"}},{"id":4157231,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T22:01:56.000Z","date":"2017-11-17","kind":"sale","acquired":false,"shares":24400,"price":140.22,"value":3421368.0,"ownership":{"direct":false,"nature":"Indirect"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.15 to $141.00, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates  (the \"Funds\").   Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP.   By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds."}],"balance_after":90251,"source":{"system":"sec-edgar","filing":"0000886163-17-000144","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616317000144/edgardoc.xml","form_type":"4"}},{"id":4224899,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-25T21:36:15.000Z","date":"2017-08-23","kind":"sale","acquired":false,"shares":2000,"price":127.99,"value":255980.0,"ownership":{"direct":false,"nature":"Indirect"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the \"Funds\"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds."}],"balance_after":114651,"source":{"system":"sec-edgar","filing":"0000886163-17-000108","document":"wf-form4_150369696228577.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616317000108/wf-form4_150369696228577.xml","form_type":"4"}},{"id":4303739,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-05-27T00:15:43.000Z","date":"2017-05-25","kind":"grant","acquired":true,"shares":2456,"price":113.5,"value":278756.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 25, 2017.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":2456,"derivative":{"exercise_price":113.5,"expiration_date":"2027-05-25","underlying":"Common Stock","underlying_shares":2456},"source":{"system":"sec-edgar","filing":"0000886163-17-000070","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616317000070/edgardoc.xml","form_type":"4"}},{"id":4303738,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-27T00:15:43.000Z","date":"2017-05-25","kind":"grant","acquired":true,"shares":666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 25, 2017  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":59625,"source":{"system":"sec-edgar","filing":"0000886163-17-000070","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616317000070/edgardoc.xml","form_type":"4"}},{"id":4306277,"issuer":{"id":165961,"kind":"organization","name":"Aralez Pharmaceuticals Inc.","symbol":"ARLZ"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, without par value","published_at":"2017-05-24T10:07:46.000Z","date":"2017-05-23","kind":"sale","acquired":false,"shares":104176,"price":1.4099,"value":146877.7424,"ownership":{"direct":false,"nature":"By JALAA Equities, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $1.40 to $1.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner.  By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-17-034708","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1376960/000110465917034708/a4.xml","form_type":"4"}},{"id":4306276,"issuer":{"id":165961,"kind":"organization","name":"Aralez Pharmaceuticals Inc.","symbol":"ARLZ"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, without par value","published_at":"2017-05-24T10:07:46.000Z","date":"2017-05-22","kind":"sale","acquired":false,"shares":233468,"price":1.4236,"value":332365.0448,"ownership":{"direct":false,"nature":"By JALAA Equities, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $1.40 to $1.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner.  By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP."}],"balance_after":104176,"source":{"system":"sec-edgar","filing":"0001104659-17-034708","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1376960/000110465917034708/a4.xml","form_type":"4"}},{"id":4306275,"issuer":{"id":165961,"kind":"organization","name":"Aralez Pharmaceuticals Inc.","symbol":"ARLZ"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, without par value","published_at":"2017-05-24T10:07:46.000Z","date":"2017-05-19","kind":"sale","acquired":false,"shares":51041,"price":1.5587,"value":79557.6067,"ownership":{"direct":false,"nature":"By JALAA Equities, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.50 to $1.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 45,469 shares issued in connection with a previously exercised warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner.  By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP."}],"balance_after":337644,"source":{"system":"sec-edgar","filing":"0001104659-17-034708","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376960/000110465917034708/a4.xml","form_type":"4"}},{"id":4316948,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2017-05-17T17:43:02.000Z","date":"2017-05-15","kind":"purchase","acquired":true,"shares":361,"price":8.95,"value":3230.95,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016."}],"balance_after":242433,"source":{"system":"sec-edgar","filing":"0001104659-17-033512","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465917033512/a4.xml","form_type":"4"}},{"id":4322605,"issuer":{"id":165961,"kind":"organization","name":"Aralez Pharmaceuticals Inc.","symbol":"ARLZ"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2017-05-13T01:50:12.000Z","date":"2017-05-11","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests in one installment on May 11, 2018, subject to the director's continued service on the Board as of such date."}],"balance_after":15000,"derivative":{"exercise_price":1.56,"expiration_date":"2027-05-11","underlying":"Common Shares, without par value","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-17-032406","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1376960/000110465917032406/a4.xml","form_type":"4"}},{"id":4322604,"issuer":{"id":165961,"kind":"organization","name":"Aralez Pharmaceuticals Inc.","symbol":"ARLZ"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, without par value","published_at":"2017-05-13T01:50:12.000Z","date":"2017-05-11","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted Stock Units, all of which vest on May 11, 2018, subject to the director's continued service on the Board as of such date.  Vested shares will be delivered to the Reporting Person on the earlier of the date that the Reporting Person ceases to provide services to the Board and the date of a Change of Control, as defined in the Issuer's 2016 Amended and Restated Long-Term Incentive Plan, in either case provided that the Restricted Stock Units are vested on such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 7,500 Common Shares and 7,500 Restricted Stock Units."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001104659-17-032406","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376960/000110465917032406/a4.xml","form_type":"4"}},{"id":4323868,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-13T00:06:12.000Z","date":"2017-05-12","kind":"sale","acquired":false,"shares":14582,"price":111.8731,"value":1631333.5442,"ownership":{"direct":false,"nature":"Indirect"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.99 to $112.97, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates  (the \"Funds\").   Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP.   By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds."}],"balance_after":116651,"source":{"system":"sec-edgar","filing":"0000886163-17-000057","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616317000057/edgardoc.xml","form_type":"4"}},{"id":4323867,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-13T00:06:12.000Z","date":"2017-05-11","kind":"sale","acquired":false,"shares":22665,"price":110.0386,"value":2494024.869,"ownership":{"direct":false,"nature":"Indirect"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.49 to $111.00, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates  (the \"Funds\").   Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP.   By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds."}],"balance_after":131233,"source":{"system":"sec-edgar","filing":"0000886163-17-000057","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616317000057/edgardoc.xml","form_type":"4"}},{"id":4345509,"issuer":{"id":165961,"kind":"organization","name":"Aralez Pharmaceuticals Inc.","symbol":"ARLZ"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, without par value","published_at":"2017-04-25T20:30:45.000Z","date":"2016-09-16","kind":"purchase","acquired":true,"shares":295929,"price":5.855,"value":1732664.295,"ownership":{"direct":false,"nature":"By JALAA Equities, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner.  By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP."}],"balance_after":343216,"source":{"system":"sec-edgar","filing":"0001104659-17-025903","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376960/000110465917025903/a4.xml","form_type":"4"}},{"id":4419218,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-01T01:30:40.000Z","date":"2017-02-28","kind":"sale","acquired":false,"shares":7000,"price":107.58,"value":753060.0,"ownership":{"direct":false,"nature":"Indirect"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.49 to $107.94, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates  (the \"Funds\").   Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP.   By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds."}],"balance_after":153898,"source":{"system":"sec-edgar","filing":"0000886163-17-000033","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616317000033/edgardoc.xml","form_type":"4"}},{"id":4419217,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-01T01:30:40.000Z","date":"2017-02-27","kind":"sale","acquired":false,"shares":25000,"price":106,"value":2650000.0,"ownership":{"direct":false,"nature":"Indirect"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.99 to $106.99, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates  (the \"Funds\").   Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP.   By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds."}],"balance_after":160898,"source":{"system":"sec-edgar","filing":"0000886163-17-000033","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616317000033/edgardoc.xml","form_type":"4"}},{"id":4494565,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2017-01-10T21:10:57.000Z","date":"2017-01-08","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22500,"derivative":{"exercise_price":3.73,"exercise_date":"2017-01-08","expiration_date":"2024-01-08","underlying":"Common Stock, par value $0.01 per share","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001104659-17-001800","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465917001800/a4.xml","form_type":"4"}},{"id":4512452,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-27T16:12:32.000Z","date":"2016-12-22","kind":"grant","acquired":true,"shares":9600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The common shares underlying this stock option award will vest in equal monthly installments over 36 months, beginning one month after the grant date."}],"balance_after":9600,"derivative":{"exercise_price":8.65,"expiration_date":"2026-12-22","underlying":"Common Shares","underlying_shares":9600},"source":{"system":"sec-edgar","filing":"0001104659-16-163887","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465916163887/a4.xml","form_type":"4"}},{"id":4537863,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, without par value","published_at":"2016-12-01T16:06:35.000Z","date":"2016-11-29","kind":"grant","acquired":true,"shares":82765,"ownership":{"direct":false,"nature":"By JLD Investments, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 80,700 shares of Aegerion common stock pursuant to the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest."}],"balance_after":82765,"source":{"system":"sec-edgar","filing":"0001104659-16-160115","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465916160115/a4.xml","form_type":"4"}},{"id":4537862,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, without par value","published_at":"2016-12-01T16:06:35.000Z","date":"2016-11-29","kind":"grant","acquired":true,"shares":31280,"ownership":{"direct":false,"nature":"By JLV Investments, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 30,500 shares of Aegerion common stock pursuant to the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest."}],"balance_after":31280,"source":{"system":"sec-edgar","filing":"0001104659-16-160115","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465916160115/a4.xml","form_type":"4"}}],"next_cursor":"2016-12-01T16:06:35.000000Z,4537862"}